Latest Content

New data tracks young-onset colorectal cancer, Medicaid health gaps, pediatric diabetes spikes, and drug-pricing shifts reshaping US care in 2026 highlight this weekly roundup.

Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.

The politicization of public health is eroding vaccine confidence, risking lower uptake and potential disease outbreaks, says Noel T. Brewer, PhD.

Racial disparities in food insecurity persisted despite income level in US households between 2000 and 2023.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The Go for Bold initiative, which aims to help individuals in Washington County, Maryland, lose 1 million lb by 2030, serves as a successful, replicable model for community-wide health improvement.

Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar.

Sequencing CDK4/6i to the second line rather than the first appears to produce equivalent survival for most patients with meaningfully less treatment burden.